COVID,O
‐,O
19,NUMBER
Outpatient,O
Screening,O
:,O
a,O
Prediction,O
Score,O
for,O
Adverse,O
Events,O
Haoqi,O
Sun,O
*,O
.,O
1.3,NUMBER
Aayushee,O
Jain,RELIGION
*,O
.,O
1.3,NUMBER
Michael,PERSON
J.,PERSON
Leone,PERSON
*,O
.,O
1.2,NUMBER
Haitham,PERSON
S.,PERSON
Alabsi,PERSON
.,O
2.4.9,NUMBER
Laura,PERSON
Brenner,PERSON
.1.3,O
Elissa,PERSON
Ye,PERSON
.,O
Wendong,PERSON
Ge,ORGANIZATION
.,O
1.3,NUMBER
Yu,O
‐,O
Ping,O
Shao,O
.,O
1Christine,O
Boutros,O
.,O
5.6,NUMBER
Ruopeng,PERSON
Wang,PERSON
.,O
1.3,NUMBER
Ryan,PERSON
Tesh,PERSON
.,O
1Colin,O
Magdamo,O
.,O
1Sarah,O
I.,PERSON
Collens,PERSON
.,O
1.3,NUMBER
Wolfgang,PERSON
Ganglberg,PERSON
‐,O
er,O
.,O
2.7,NUMBER
Ingrid,PERSON
V.,PERSON
Bassett,PERSON
.,O
2.9,NUMBER
James,PERSON
B.,PERSON
Meigs,PERSON
.,O
2.5.6,NUMBER
Jayashree,PERSON
Kalpathy,O
‐,O
Cramer,PERSON
.,O
Matthew,PERSON
D.,PERSON
Li,PERSON
.,O
2.7.9.10,NUMBER
Jacqueline,PERSON
Chu,PERSON
.,O
2.8,NUMBER
Michael,PERSON
L.,PERSON
Dougan,PERSON
.,O
1.2,NUMBER
Lawrence,PERSON
Stratton,PERSON
.,O
1.2,NUMBER
Jonathan,PERSON
Rosand,PERSON
.,O
2.5.6.11,NUMBER
Bruce,PERSON
Fischl,PERSON
.,O
1.2,NUMBER
Sudeshna,O
Das,O
.,O
1.2,NUMBER
Shibani,PERSON
Mukerji,PERSON
**,O
.,O
2.7,NUMBER
Gregory,PERSON
K.,PERSON
Robbins,PERSON
**,O
.,O
1.2.3,NUMBER
M.,NUMBER
Brandon,PERSON
Westover,PERSON
**,O
Department,O
of,O
Neurology,O
.,O
Massachusetts,ORGANIZATION
General,ORGANIZATION
Hospital,ORGANIZATION
.,O
Boston,CITY
.,O
MA,PERSON
Clinical,PERSON
Data,O
AI,O
Center,O
(,O
CDAC,O
),O
.,O
Massachusetts,ORGANIZATION
General,ORGANIZATION
Hospital,ORGANIZATION
.,O
Boston,CITY
.,O
MA,STATE_OR_PROVINCE
Division,O
of,O
Pulmonary,O
and,O
Critical,O
Care,O
Medicine,O
.,O
Massachusetts,STATE_OR_PROVINCE
General,ORGANIZATION
Hospital,ORGANIZATION
.,O
Boston,CITY
.,O
MA,ORGANIZATION
Department,ORGANIZATION
of,ORGANIZATION
Radiology,ORGANIZATION
.,O
Massachu,O
‐,O
setts,O
General,ORGANIZATION
Hospital,ORGANIZATION
.,O
Boston,CITY
.,O
MA,PERSON
Athinoula,PERSON
A.,PERSON
Martinos,PERSON
Center,PERSON
for,O
Biomedical,ORGANIZATION
Imaging,ORGANIZATION
.,O
Boston,CITY
.,O
MA,STATE_OR_PROVINCE
Division,O
of,O
Infectious,O
Dis,O
‐,O
eases,O
.,O
Massachusetts,ORGANIZATION
General,ORGANIZATION
Hospital,ORGANIZATION
.,O
Boston,CITY
.,O
MA,STATE_OR_PROVINCE
Division,O
of,O
Gastroenterology,O
.,O
Massachusetts,ORGANIZATION
General,ORGANIZATION
Hospital,ORGANIZATION
.,O
Boston,CITY
.,O
MA,STATE_OR_PROVINCE
Di,O
‐,O
vision,O
of,O
General,ORGANIZATION
Internal,ORGANIZATION
Medicine,ORGANIZATION
.,O
Massachusetts,STATE_OR_PROVINCE
General,TITLE
Hospi,O
‐,O
tal,O
.,O
Boston,CITY
.,O
MA,ORGANIZATION
MGH,ORGANIZATION
Chelsea,ORGANIZATION
HealthCare,ORGANIZATION
Center,ORGANIZATION
.,O
Chelsea,PERSON
.,O
MA,STATE_OR_PROVINCE
MIT,O
HST,ORGANIZATION
/,ORGANIZATION
CSAIL,ORGANIZATION
.,O
Cambridge,CITY
.,O
MA,STATE_OR_PROVINCE
death,O
in,O
patients,O
at,O
risk,O
for,O
COVID,O
‐,O
19,NUMBER
presenting,O
for,O
urgent,O
care,O
during,O
the,O
Massachusetts,STATE_OR_PROVINCE
outbreak,O
.,O
Methods,O
.,O
Single,O
‐,O
center,O
study,O
of,O
adult,O
outpatients,O
seen,O
in,O
respi,O
‐,O
ratory,O
illness,CAUSE_OF_DEATH
clinics,O
(,O
RICs,O
),O
or,O
the,O
emergency,O
department,O
(,O
ED,O
),O
.,O
including,O
development,O
(,O
n,O
=,O
9381,NUMBER
.,O
March,DATE
7,DATE
‐,O
May,DATE
2,DATE
),O
and,O
prospective,O
(,O
n,O
=,O
2205,DATE
.,DATE
May,DATE
3,DATE
‐,O
14,NUMBER
),O
cohorts,O
.,O
Data,O
was,O
queried,O
from,O
Partners,O
En,O
‐,O
terprise,O
Data,O
Warehouse,O
.,O
Outcomes,O
were,O
hospitalization,O
.,O
critical,O
illness,CAUSE_OF_DEATH
or,O
death,O
within,O
7,DURATION
days,DURATION
.,O
We,O
developed,O
the,O
COVID,O
‐,O
19,NUMBER
Acuity,O
Score,O
(,O
CoVA,O
),O
using,O
automatically,O
extracted,O
data,O
from,O
the,O
elec,O
‐,O
tronic,O
medical,O
record,O
and,O
learning,O
‐,O
to,O
‐,O
rank,O
ordinal,O
logistic,O
re,O
‐,O
gression,O
modeling,O
.,O
Calibration,O
was,O
assessed,O
using,O
predicted,O
‐,O
to,O
‐,O
observed,O
ratio,O
(,O
E,O
/,O
O,O
),O
.,O
Discrimination,O
was,O
assessed,O
by,O
C,O
‐,O
statis,O
‐,O
tics,O
(,O
AUC,O
),O
.,O
Results,O
.,O
In,O
the,O
development,O
cohort,O
.,O
27.3,PERCENT
%,PERCENT
.,O
7.2,PERCENT
%,PERCENT
.,O
and,O
1.1,PERCENT
%,PERCENT
of,O
patients,O
experienced,O
hospitalization,O
.,O
critical,O
illness,CAUSE_OF_DEATH
.,O
or,O
death,O
.,O
respectively,O
;,O
and,O
in,O
the,O
prospective,O
cohort,O
.,O
26.1,PERCENT
%,PERCENT
.,O
6.3,PERCENT
%,PERCENT
.,O
and,O
0.5,PERCENT
%,PERCENT
.,O
CoVA,O
showed,O
excellent,O
performance,O
in,O
the,O
develop,O
‐,O
ment,O
cohort,O
(,O
concurrent,O
validation,O
),O
for,O
hospitalization,O
(,O
E,O
/,O
O,O
:,O
1.00,NUMBER
.,O
AUC,O
:,O
0.80,NUMBER
),O
;,O
for,O
critical,O
illness,CAUSE_OF_DEATH
(,O
E,O
/,O
O,O
:,O
1.00,NUMBER
.,O
AUC,O
:,O
0.82,NUMBER
),O
;,O
and,O
for,O
death,O
(,O
E,O
/,O
O,O
:,O
1.00,NUMBER
.,O
AUC,O
:,O
0.87,NUMBER
),O
.,O
Performance,O
in,O
the,O
prospective,O
cohort,O
(,O
prospective,O
validation,O
),O
was,O
similar,O
for,O
hos,O
‐,O
pitalization,O
(,O
E,O
/,O
O,O
:,O
1.01,NUMBER
.,O
AUC,O
:,O
0.76,NUMBER
),O
;,O
for,O
critical,O
illness,CAUSE_OF_DEATH
(,O
E,O
/,O
O,O
1.03,NUMBER
.,O
AUC,O
:,O
0.79,NUMBER
),O
;,O
and,O
for,O
death,O
(,O
E,O
/,O
O,O
:,O
1.63,NUMBER
.,O
AUC,O
=,O
0.93,NUMBER
),O
.,O
Among,O
30,NUMBER
predictors,O
.,O
the,O
top,O
five,NUMBER
were,O
age,O
.,O
diastolic,O
blood,O
pressure,O
.,O
blood,O
oxygen,O
saturation,O
.,O
COVID,O
‐,O
19,NUMBER
testing,O
status,O
.,O
and,O
respiratory,O
rate,O
.,O
related,O
to,O
COVID,O
‐,O
19,NUMBER
infection,CAUSE_OF_DEATH
in,O
the,O
outpatient,O
setting,O
.,O
The,O
COVID,O
‐,O
19,NUMBER
pandemic,O
has,O
presented,O
unparalleled,O
challenges,O
for,O
healthcare,O
systems,O
around,O
the,O
world,O
[,O
18,NUMBER
],O
.,O
The,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
virus,O
first,ORDINAL
appeared,O
in,O
Wuhan,CITY
.,O
China,COUNTRY
in,O
December,DATE
2019,DATE
.,O
The,O
first,ORDINAL
US,COUNTRY
case,O
was,O
confirmed,O
on,O
January,DATE
20,DATE
[,O
9,NUMBER
],O
.,O
followed,O
by,O
exponential,O
spread,O
within,O
the,O
US,COUNTRY
[,O
10,NUMBER
],O
.,O
By,O
the,DATE
end,DATE
of,DATE
April,DATE
.,O
Massachusetts,STATE_OR_PROVINCE
was,O
the,O
third,ORDINAL
hardest,O
hit,O
state,O
.,O
trailing,O
only,O
New,STATE_OR_PROVINCE
York,STATE_OR_PROVINCE
and,O
New,O
Jer,O
‐,O
sey,O
[,O
11,NUMBER
],O
.,O
Within,O
Massachusetts,STATE_OR_PROVINCE
.,O
Boston,CITY
and,O
Chelsea,PERSON
were,O
epicenters,O
for,O
the,O
spread,O
of,O
COVID,O
‐,O
19,NUMBER
.,O
In,O
anticipation,O
of,O
the,O
surge,O
of,O
COVID,O
‐,O
19,NUMBER
patients,O
and,O
to,O
help,O
limit,O
viral,O
spread,O
.,O
Massachusetts,STATE_OR_PROVINCE
General,ORGANIZATION
Hospital,ORGANIZATION
(,O
MGH,ORGANIZATION
),O
closed,O
most,O
outpatient,O
and,O
urgent,O
care,O
clinics,O
and,O
set,O
up,O
new,O
Respiratory,O
Illness,CAUSE_OF_DEATH
Clinics,O
(,O
RICs,O
),O
on,O
March,DATE
7,DATE
.,DATE
2020,DATE
to,O
manage,O
patients,O
with,O
symptoms,O
of,O
a,O
respiratory,O
infection,CAUSE_OF_DEATH
.,O
These,O
clinics,O
were,O
staffed,O
by,O
clinicians,O
and,O
nurses,O
reassigned,O
from,O
other,O
areas,O
.,O
most,O
with,O
little,O
urgent,O
care,O
experi,O
‐,O
ence,O
.,O
COVID,O
‐,O
19,NUMBER
suspected,O
cases,O
were,O
also,O
screened,O
in,O
the,O
Emer,O
‐,O
gency,O
Department,O
(,O
ED,O
),O
.,O
Due,O
to,O
high,O
case,O
volumes,O
and,O
precautions,O
for,O
staff,O
and,O
patients,O
.,O
visit,O
duration,O
and,O
extent,O
of,O
clinical,O
as,O
‐,O
sessments,O
for,O
most,O
patients,O
were,O
curtailed,O
.,O
In,O
addition,O
to,O
limit,O
‐,O
ed,O
clinical,O
assessment,O
.,O
triage,O
decisions,O
were,O
complicated,O
by,O
COVID,O
‐,O
19s,O
biphasic,O
clinical,O
course,O
.,O
Patients,O
who,O
initially,O
present,DATE
with,O
mild,O
symptoms,O
often,O
later,O
return,O
for,O
hospital,O
admis,O
‐,O
sion,O
.,O
and,O
many,O
subsequently,O
suffer,O
adverse,O
events,O
including,O
ICU,O
transfer,O
.,O
mechanical,O
ventilation,O
(,O
MV,O
),O
or,O
death,O
.,O
Various,O
predic,O
‐,O
tion,O
rules,O
have,O
been,O
proposed,O
.,O
but,O
to,O
our,O
knowledge,O
few,O
have,O
been,O
prospectively,O
validated,O
.,O
and,O
most,O
were,O
developed,O
for,O
the,O
inpa,O
‐,O
tient,O
setting,O
rather,O
than,O
outpatient,O
To,O
help,O
frontline,O
clinicians,O
appropriately,O
triage,O
and,O
plan,O
follow,O
‐,O
up,O
care,O
for,O
patients,O
pre,O
‐,O
senting,O
for,O
COVID,O
‐,O
19,NUMBER
screening,O
and,O
not,O
requiring,O
immediate,O
hospi,O
‐,O
talization,O
.,O
we,O
developed,O
an,O
outpatient,O
screening,O
score,O
.,O
COVID,O
‐,O
19,NUMBER
Acuity,O
Score,O
(,O
CoVA,O
),O
.,O
that,O
could,O
be,O
incorporated,O
into,O
an,O
electron,O
‐,O
ic,O
medical,O
record,O
(,O
EMR,O
),O
system,O
.,O
We,O
used,O
data,O
from,O
MGHs,O
newly,O
formed,O
RIC,O
clinics,O
and,O
the,O
emergency,O
department,O
.,O
CoVA,O
assigns,O
acuity,O
levels,O
based,O
on,O
demographic,O
.,O
clinical,O
.,O
radiographic,O
.,O
and,O
medical,O
history,O
variables,O
.,O
and,O
provides,O
predicted,O
probabilities,O
for,O
hospital,O
admission,O
.,O
ICU,O
admission,O
or,O
MV,O
.,O
or,O
death,O
within,O
7,NUMBER
Study,O
Population,O
We,O
included,O
data,O
from,O
patients,O
seen,O
in,O
MGH,O
RIC,O
clinics,O
and,O
ED,O
between,O
March,DATE
7,DATE
and,O
May,DATE
14,DATE
.,O
Patients,O
were,O
divided,O
into,O
two,NUMBER
mutually,O
exclusive,O
cohorts,O
.,O
a,O
development,O
cohort,O
(,O
March,DATE
7,NUMBER
to,O
May,DATE
2,DATE
.,DATE
2020,DATE
.,O
n,O
=,O
9381,NUMBER
),O
;,O
and,O
prospective,O
cohort,O
(,O
May,DATE
3,DATE
to,O
May,DATE
14,NUMBER
.,O
2020,DATE
.,O
n,O
=,O
2205,DATE
),O
.,O
Inclusion,O
criteria,O
were,O
:,O
(,O
1,NUMBER
),O
MGH,O
RIC,O
or,O
ED,O
visit,O
between,O
March,DATE
7th,DATE
and,O
May,DATE
14th,DATE
.,DATE
2020,DATE
;,O
(,O
2,NUMBER
),O
age,O
18,DURATION
years,DURATION
;,O
and,O
(,O
3,NUMBER
),O
reason,O
for,O
visit,O
was,O
cough,O
.,O
fever,CAUSE_OF_DEATH
.,O
shortness,O
of,O
breath,O
.,O
COVID,O
‐,O
related,O
.,O
or,O
potentially,O
related,O
swab,O
without,O
a,O
clinical,O
as,O
‐,O
sessment,O
were,O
excluded,O
;,O
and,O
(,O
2,NUMBER
),O
Patients,O
with,O
visits,O
in,O
both,O
de,O
‐,O
velopment,O
and,O
prospective,O
cohorts,O
are,O
excluded,O
.,O
to,O
ensure,O
the,O
score,O
is,O
not,O
overfit,O
to,O
those,O
patients,O
.,O
A,O
data,O
flowchart,O
is,O
de,O
‐,O
velopment,O
cohort,O
.,O
we,O
randomly,O
sampled,O
one,NUMBER
visit,O
from,O
each,O
pa,O
‐,O
tient,O
.,O
In,O
the,O
prospective,O
cohort,O
.,O
we,O
chose,O
the,O
most,O
recent,O
visit,O
from,O
each,O
patient,O
.,O
Primary,O
Outcome,O
The,O
primary,O
outcome,O
was,O
the,O
occurrence,O
of,O
an,O
adverse,O
event,O
within,O
7,DURATION
days,DURATION
following,O
an,O
outpa,O
‐,O
tient,O
medical,O
encounter,O
.,O
including,O
either,O
hospitalization,O
at,O
MGH,ORGANIZATION
.,O
critical,O
illness,CAUSE_OF_DEATH
(,O
defined,O
as,O
ICU,O
care,O
and,O
/,O
or,O
mechanical,O
ventila,O
‐,O
tion,O
),O
.,O
or,O
death,O
.,O
The,O
prediction,O
horizon,O
was,O
set,O
to,O
7,DURATION
days,DURATION
because,O
this,O
period,O
was,O
considered,O
meaningful,O
by,O
our,O
frontline,O
teams,O
for,O
clinical,O
decision,O
‐,O
making,O
(,O
e.g.,O
.,O
regarding,O
whether,O
to,O
send,O
a,O
pa,O
‐,O
tient,O
home,O
or,O
to,O
the,O
emergency,O
department,O
.,O
or,O
to,O
follow,O
up,O
with,O
phone,O
calls,O
),O
.,O
and,O
because,O
empirically,O
.,O
within,O
the,O
model,TITLE
develop,O
‐,O
ment,O
cohort,O
most,O
adverse,O
events,O
occurred,O
within,O
7,DURATION
days,DURATION
of,O
initial,O
We,O
selected,O
98,NUMBER
variables,O
that,O
were,O
routinely,O
available,O
in,O
the,O
outpatient,O
setting,O
during,O
the,O
COVID,O
‐,O
19,NUMBER
pandemic,O
to,O
serve,O
as,O
can,O
‐,O
didate,O
predictors,O
.,O
These,O
included,O
demographic,O
variables,O
:,O
age,O
.,O
gender,O
.,O
tobacco,CAUSE_OF_DEATH
use,O
history,O
.,O
most,O
recent,O
body,O
mass,O
index,O
(,O
BMI,O
),O
within,O
the,O
preceding,O
month,DURATION
(,O
represented,O
as,O
binary,O
variables,O
des,O
‐,O
ignated,O
as,O
high,O
BMI,O
.,O
>,O
35kg,NUMBER
/,O
m2,O
.,O
and,O
low,O
BMI,O
.,O
<,O
18.5,NUMBER
kg,O
/,O
m2,O
),O
.,O
the,O
most,O
recent,O
vital,O
signs,O
(,O
blood,O
pressure,O
.,O
respiratory,O
rate,O
.,O
heart,O
rate,O
.,O
temperature,O
.,O
blood,O
oxygen,O
saturation,O
level,O
(,O
SpO2,O
),O
),O
within,O
the,O
preceding,O
3,DURATION
days,DURATION
;,O
COVID,O
testing,O
status,O
(,O
See,O
Supplemental,O
Section,O
Predictor,O
encoding,O
for,O
encoding,O
details,O
),O
;,O
specific,O
symptoms,O
sug,O
‐,O
gestive,O
of,O
COVID,O
‐,O
19,NUMBER
(,O
anosmia,O
.,O
dysgeusia,O
based,O
on,O
ICD,O
‐,O
10,NUMBER
codes,O
),O
.,O
and,O
pre,O
‐,O
existing,O
medical,O
diagnoses,O
.,O
coded,O
as,O
present,DATE
or,O
absent,O
based,O
on,O
groups,O
of,O
billing,O
codes,O
(,O
ICD,O
‐,O
10,NUMBER
recorded,O
on,O
or,O
before,O
the,DATE
day,DATE
of,O
presentation,O
.,O
The,O
Weighted,MISC
Charlson,MISC
Comorbidity,MISC
Index,MISC
(,O
CCI,ORGANIZATION
),O
was,O
computed,O
based,O
on,O
groups,O
of,O
ICDs,O
using,O
the,O
wscore,O
from,O
the,O
R,O
package,O
comorbidity,O
[,O
14,NUMBER
],O
.,O
We,O
omitted,O
race,O
and,O
ethnicity,O
as,O
predictors,O
because,O
(,O
1,NUMBER
),O
we,O
have,O
found,O
that,O
these,O
variables,O
were,O
often,O
unavailable,O
or,O
inaccurately,O
recorded,O
.,O
especially,O
ethnicity,O
;,O
and,O
(,O
2,NUMBER
),O
we,O
wanted,O
to,O
limit,O
the,O
influence,O
of,O
local,O
demographic,O
patterns,O
on,O
the,O
score,O
.,O
which,O
might,O
limit,O
the,O
ability,O
to,O
general,TITLE
‐,O
ize,O
to,O
external,O
For,O
patients,O
who,O
underwent,O
chest,O
X,O
‐,O
ray,O
(,O
CXR,O
),O
imaging,O
during,O
these,O
encounters,O
.,O
we,O
identified,O
groups,O
of,O
extract,O
‐,O
ed,O
key,O
words,O
.,O
phrases,O
.,O
and,O
word,O
patterns,O
describing,O
abnormal,O
findings,O
.,O
Next,O
.,O
a,O
pulmonary,O
and,O
critical,O
care,O
medicine,O
physician,TITLE
(,O
LB,O
),O
categorized,O
these,O
phrases,O
into,O
groups,O
.,O
Five,NUMBER
groups,O
were,O
identified,O
:,O
multifocal,O
.,O
patterns,O
typical,O
for,O
COVID,O
‐,O
19,NUMBER
(,O
pneumonia,CAUSE_OF_DEATH
.,O
bronchopneumonia,O
.,O
Acute,O
Respiratory,O
Distress,O
Syndrome,O
(,O
ARDS,O
),O
),O
.,O
patchy,O
consolidation,O
.,O
peripheral,O
or,O
interstitial,O
opacity,O
.,O
or,O
hazy,O
or,O
airspace,O
opacities,O
.,O
not,O
present,DATE
or,O
unavailable,O
.,O
Data,O
Prepro,O
‐,O
cessing,O
and,O
Selection,O
of,O
Predictor,O
Variables,O
S5,O
),O
.,O
Unavailable,O
values,O
were,O
imputed,O
using,O
K,O
‐,O
nearest,O
neighbors,O
(,O
KNN,O
),O
[,O
15,NUMBER
],O
.,O
where,O
the,O
value,O
of,O
K,O
was,O
determined,O
by,O
minimizing,O
the,O
imputation,O
error,O
on,O
a,O
subset,O
without,O
unavailable,O
data,O
by,O
randomly,O
masking,O
vari,O
‐,O
ables,O
according,O
to,O
the,O
pattern,O
of,O
unavailability,O
in,O
the,O
overall,O
data,O
.,O
Note,O
that,O
we,O
did,O
not,O
impute,O
CXR,O
predictors,O
or,O
COVID,O
status,O
for,O
patients,O
who,O
did,O
not,O
have,O
either,O
of,O
them,O
available,O
.,O
Instead,O
.,O
for,O
these,O
we,O
coded,O
unavailability,O
explicitly,O
(,O
described,O
above,O
),O
.,O
Predictors,O
were,O
standardized,O
to,O
zero,NUMBER
mean,O
and,O
unit,O
standard,O
devi,O
‐,O
ation,O
using,O
z,O
‐,O
score,O
transformation,O
we,O
used,O
ANOVA,ORGANIZATION
statistics,O
to,O
identify,O
predictors,O
associated,O
with,O
hospitalization,O
.,O
ICU,O
care,O
or,O
MV,O
.,O
or,O
death,O
.,O
At,O
0.05,NUMBER
significance,O
level,O
.,O
we,O
identified,O
65,NUMBER
pre,O
‐,O
dictors,O
to,O
carry,O
forward,O
into,O
the,O
model,TITLE
fitting,O
selection,O
(,O
LASSO,O
),O
regression,O
during,O
the,O
model,TITLE
fitting,O
procedure,O
to,O
select,O
a,O
reduced,O
subset,O
of,O
highly,O
predictive,O
variables,O
.,O
Model,TITLE
Development,O
We,O
as,O
‐,O
signed,O
an,O
ordinal,O
scale,O
to,O
adverse,O
events,O
.,O
including,O
no,O
event,O
.,O
hospitalized,O
.,O
ICU,O
care,O
and,O
/,O
or,O
MV,O
.,O
and,O
death,O
.,O
We,O
used,O
an,O
implemen,O
‐,O
tation,O
of,O
ordinal,O
regression,O
:,O
pairwise,O
learning,O
to,O
rank,O
(,O
LTR,O
),O
with,O
LASSO,PERSON
penalized,O
logistic,O
regression,O
[,O
16.17,NUMBER
],O
.,O
Training,O
in,O
‐,O
volves,O
learning,O
to,O
predict,O
which,O
of,O
a,O
pair,O
of,O
patients,O
will,O
have,O
a,O
worse,O
outcome,O
.,O
On,O
biological,O
grounds,O
.,O
and,O
to,O
address,O
co,O
‐,O
linear,O
‐,O
ity,O
among,O
predictors,O
.,O
we,O
constrained,O
the,O
model,TITLE
optimization,O
to,O
allow,O
only,O
non,O
‐,O
negative,O
coefficients,O
for,O
CXR,O
predictors,O
.,O
medical,O
comorbidities,O
.,O
CCI,ORGANIZATION
.,O
and,O
history,O
of,O
current,DATE
or,O
past,DATE
tobacco,CAUSE_OF_DEATH
use,O
;,O
and,O
unconstrained,O
for,O
other,O
predictors,O
.,O
Model,TITLE
training,O
and,O
pre,O
‐,O
liminary,O
evaluation,O
of,O
model,TITLE
performance,O
was,O
performed,O
using,O
the,O
development,O
cohort,O
.,O
using,O
nested,O
5,NUMBER
‐,O
fold,O
cross,O
validation,O
(,O
CV,O
),O
(,O
Supplemental,O
Materials,O
and,O
probabilities,O
for,O
hospitalization,O
and,O
for,O
critical,O
illness,CAUSE_OF_DEATH
or,O
death,O
within,O
7,DURATION
days,DURATION
.,O
The,O
final,O
model,TITLE
was,O
tested,O
on,O
the,O
prospective,O
validation,O
cohort,O
.,O
Performance,O
is,O
re,O
‐,O
ported,O
both,O
for,O
the,O
development,O
cohort,O
(,O
results,O
from,O
cross,O
vali,O
‐,O
dation,O
),O
.,O
and,O
for,O
the,O
prospective,O
cohort,O
.,O
Statistical,O
Analysis,O
of,O
CoVA,O
Predictive,O
Performance,O
We,O
summarized,O
the,O
distribution,O
of,O
co,O
‐,O
hort,O
characteristics,O
and,O
adverse,O
events,O
using,O
event,O
counts,O
and,O
proportions,O
for,O
categorical,O
predictors,O
.,O
and,O
mean,O
and,O
standard,O
de,O
‐,O
viation,O
for,O
continuous,O
variables,O
.,O
For,O
model,TITLE
calibration,O
.,O
an,O
ex,O
‐,O
pected,O
‐,O
to,O
‐,O
observed,O
ratio,O
(,O
E,O
/,O
O,O
),O
[,O
18,NUMBER
],O
of,O
1.0,NUMBER
indicates,O
that,O
the,O
num,O
‐,O
ber,O
of,O
expected,O
events,O
equals,O
the,O
number,O
of,O
observed,O
events,O
;,O
and,O
calibration,O
slope,O
(,O
CS,O
),O
is,O
defined,O
as,O
the,O
linear,O
correlation,O
be,O
‐,O
tween,O
the,O
observed,O
O,O
and,O
expected,O
probabilities,O
E,O
.,O
where,O
the,O
ex,O
‐,O
pected,O
(,O
predicted,O
),O
values,O
(,O
E,O
),O
are,O
binned,O
into,O
quintiles,O
.,O
We,O
cal,O
‐,O
culated,O
the,O
area,O
under,O
the,O
Receiver,MISC
Operator,TITLE
Characteristic,MISC
(,O
ROC,COUNTRY
),O
curve,O
(,O
AUC,ORGANIZATION
.,O
also,O
called,O
the,O
Cstatistic,O
),O
to,O
quantify,O
how,O
well,O
CoVA,O
scores,O
discriminate,O
between,O
individuals,O
who,O
within,O
7,DURATION
days,DURATION
were,O
vs.,O
not,O
hospitalized,O
.,O
and,O
between,O
those,O
who,O
did,O
vs.,O
not,O
experi,O
‐,O
ence,O
critical,O
illness,CAUSE_OF_DEATH
(,O
ICU,O
care,O
.,O
MV,O
.,O
or,O
death,O
),O
.,O
We,O
considered,O
an,O
AUC,O
between,O
0.50,NUMBER
and,NUMBER
0.55,NUMBER
to,O
be,O
poor,O
;,O
0.55,NUMBER
and,O
0.65,NUMBER
.,O
moderate,O
;,O
0.65,NUMBER
and,O
0.75,NUMBER
.,O
negative,O
predictive,O
values,O
(,O
NPV,O
),O
at,O
the,O
90,PERCENT
%,PERCENT
sensi,O
‐,O
tivity,O
level,O
.,O
We,O
also,O
looked,O
at,O
the,O
time,DATE
course,O
of,O
adverse,O
events,O
as,O
a,O
function,O
of,O
CoVA,O
score,O
over,O
4,DURATION
weeks,DURATION
(,O
28,DURATION
days,DURATION
),O
follow,O
‐,O
ing,O
initial,O
presentation,O
to,O
the,O
RIC,O
or,O
ED,O
to,O
understand,O
the,O
prop,O
‐,O
erties,O
of,O
CoVA,O
score,O
.,O
Cohort,O
Characteristics,O
From,O
March,DATE
7,DATE
to,O
May,DATE
2,NUMBER
.,O
2020,DATE
.,O
9381,DATE
patients,O
met,O
inclusion,O
criteria,O
and,O
were,O
included,O
in,O
the,O
development,O
cohort,O
.,O
The,O
average,O
age,O
was,O
51,DURATION
years,DURATION
old,DURATION
with,O
49,PERCENT
%,PERCENT
being,O
female,O
.,O
Among,O
these,O
.,O
3344,NUMBER
(,O
35.6,PERCENT
%,PERCENT
),O
had,O
adverse,O
events,O
within,O
7,DURATION
days,DURATION
of,O
presentation,O
:,O
2562,DATE
(,O
27.3,PERCENT
%,PERCENT
),O
were,O
hospitalized,O
.,O
679,NUMBER
(,O
7.2,PERCENT
%,PERCENT
),O
received,O
ICU,O
care,O
and,O
/,O
or,O
were,O
mechanically,O
ventilated,O
.,O
and,O
103,NUMBER
(,O
1.1,PERCENT
%,PERCENT
),O
died,O
.,O
From,O
May,DATE
3,DATE
‐,DATE
14,DATE
.,DATE
2205,DATE
additional,O
patients,O
met,O
inclusion,O
criteria,O
and,O
were,O
included,O
in,O
the,O
prospective,O
cohort,O
.,O
The,O
average,O
age,O
was,O
53,DURATION
years,DURATION
old,DURATION
with,O
49,PERCENT
%,PERCENT
being,O
female,O
.,O
Among,O
these,O
.,O
726,NUMBER
(,O
32.9,PERCENT
%,PERCENT
),O
had,O
adverse,O
events,O
:,O
575,NUMBER
(,O
26.1,PERCENT
%,PERCENT
),O
were,O
hospital,O
‐,O
ized,O
.,O
139,NUMBER
(,O
6.3,PERCENT
%,PERCENT
),O
received,O
ICU,O
care,O
and,O
/,O
or,O
were,O
mechanically,O
ven,O
‐,O
tilated,O
.,O
and,O
12,NUMBER
(,O
0.5,PERCENT
%,PERCENT
),O
died,O
.,O
prospective,O
validation,O
period,O
there,O
were,O
modest,O
increases,O
in,O
the,O
proportion,O
of,O
patients,O
with,O
CXRs,O
(,O
prospective,O
52.3,PERCENT
%,PERCENT
vs.,O
development,O
41.0,PERCENT
%,PERCENT
),O
.,O
the,O
proportion,O
of,O
out,O
‐,O
patient,O
evaluations,O
performed,O
in,O
RIC,O
clinics,O
(,O
prospective,O
26.5,PERCENT
%,PERCENT
vs.,O
development,O
21.4,PERCENT
%,PERCENT
),O
.,O
and,O
in,O
testing,O
rates,O
for,O
COVID,O
‐,O
19,NUMBER
(,O
prospective,O
78.8,PERCENT
%,PERCENT
vs.,O
development,O
59.5,PERCENT
%,PERCENT
),O
.,O
Several,O
other,O
small,O
but,O
likely,O
clinically,O
insignificant,O
differences,O
between,O
cohorts,O
also,O
reached,O
statistical,O
significance,O
.,O
due,O
to,O
the,O
large,O
cohort,O
sizes,O
.,O
COVID,O
‐,O
19,NUMBER
infections,CAUSE_OF_DEATH
and,O
Predictive,O
Performance,O
CoVA,O
showed,O
excellent,O
calibration,O
and,O
discrimination,O
in,O
the,O
development,O
co,O
‐,O
hort,O
for,O
hospitalization,O
(,O
E,O
/,O
O,O
:,O
1.00,NUMBER
[,O
0.98,NUMBER
.,O
1.02,NUMBER
],O
.,O
CS,O
:,O
0.99,NUMBER
[,O
0.98,NUMBER
.,O
0.99,NUMBER
],O
.,O
AUC,O
:,O
0.80,NUMBER
[,O
0.79,NUMBER
.,O
0.81,NUMBER
],O
),O
;,O
for,O
critical,O
illness,CAUSE_OF_DEATH
(,O
E,O
/,O
O,O
:,O
1.00,NUMBER
[,O
0.93,NUMBER
.,O
1.06,NUMBER
],O
.,O
CS,O
:,O
0.98,NUMBER
[,O
0.96,NUMBER
.,O
0.99,NUMBER
],O
.,O
AUC,O
:,O
0.82,NUMBER
[,O
0.80,NUMBER
.,O
0.83,NUMBER
],O
),O
;,O
and,O
for,O
death,O
(,O
E,O
/,O
O,O
:,O
1.00,NUMBER
[,O
0.84,NUMBER
.,O
1.21,NUMBER
],O
.,O
CS,O
:,O
not,O
calculated,O
due,O
to,O
small,O
sample,O
size,O
;,O
AUC,O
:,O
0.87,NUMBER
[,O
0.83,NUMBER
.,O
0.91,NUMBER
],O
),O
.,O
Performance,O
generalized,O
to,O
the,O
prospective,O
validation,O
cohort,O
.,O
with,O
similar,O
results,O
for,O
hospitalization,O
(,O
E,O
/,O
O,O
:,O
1.01,NUMBER
[,O
0.96,NUMBER
.,O
1.07,NUMBER
],O
.,O
CS,O
:,O
0.99,NUMBER
[,O
0.98,NUMBER
.,O
1.00,NUMBER
],O
.,O
AUC,O
0.76,NUMBER
[,O
0.73,NUMBER
.,O
0.78,NUMBER
],O
),O
;,O
for,O
critical,O
illness,CAUSE_OF_DEATH
(,O
E,O
/,O
O,O
:,O
1.03,NUMBER
[,O
0.89,NUMBER
.,O
1.20,NUMBER
],O
.,O
CS,O
:,O
0.98,NUMBER
[,O
0.94,NUMBER
.,O
1.00,NUMBER
],O
.,O
AUC,O
:,O
0.79,NUMBER
[,O
0.75,NUMBER
.,O
0.82,NUMBER
],O
),O
;,O
and,O
for,O
death,O
(,O
E,O
/,O
O,O
:,O
1.63,NUMBER
[,O
1.03,NUMBER
.,O
3.25,NUMBER
],O
.,O
CS,O
:,O
not,O
calcu,O
‐,O
lated,O
due,O
to,O
small,O
sample,O
Properties,O
of,O
COVA,O
Score,O
The,O
proportion,O
of,O
patients,O
with,O
adverse,O
events,O
at,O
7,DURATION
days,DURATION
increases,O
with,O
higher,O
CoVA,O
scores,O
.,O
rising,O
from,O
18,PERCENT
%,PERCENT
with,O
CoVA,ORGANIZATION
scores,O
in,O
the,O
0,NUMBER
‐,O
20,NUMBER
range,O
.,O
to,O
88,PERCENT
%,PERCENT
for,O
those,O
with,O
scores,O
in,O
the,O
80,NUMBER
‐,O
100,NUMBER
range,O
.,O
The,O
proportion,O
underwent,O
critical,O
illness,CAUSE_OF_DEATH
or,O
death,O
also,O
rises,O
.,O
from,O
2,PERCENT
%,PERCENT
for,O
scores,O
between,O
0,NUMBER
‐,O
20,NUMBER
.,O
to,O
32,PERCENT
%,PERCENT
with,O
We,O
investigated,O
the,O
time,O
course,O
of,O
adverse,O
events,O
as,O
a,O
function,O
of,O
CoVA,O
score,O
over,O
4,DURATION
weeks,DURATION
(,O
28,NUMBER
days,DURATION
),O
following,O
initial,O
presentation,O
to,O
the,O
RIC,O
or,O
ED,O
.,O
We,O
limited,O
this,O
investigation,O
to,O
the,O
development,O
cohort,O
.,O
because,O
28,DURATION
days,DURATION
have,O
not,O
passed,O
for,O
the,O
prospective,O
validation,O
cohort,O
at,O
the,O
time,DATE
of,O
writing,O
.,O
By,O
28,DURATION
days,DURATION
.,O
3399,DATE
(,O
36,PERCENT
%,PERCENT
),O
of,O
patients,O
experienced,O
hospi,O
‐,O
talization,O
.,O
critical,O
illness,CAUSE_OF_DEATH
.,O
or,O
death,O
.,O
Of,O
these,O
.,O
3214,NUMBER
(,O
95,PERCENT
%,PERCENT
),O
oc,O
‐,O
curred,O
within,O
1,DURATION
day,DURATION
.,O
and,O
3344,DATE
(,O
98,PERCENT
%,PERCENT
),O
had,O
occurred,O
by,O
7,DURATION
days,DURATION
.,O
Crit,O
‐,O
ical,O
illness,CAUSE_OF_DEATH
or,O
death,O
occurred,O
in,O
861,NUMBER
(,O
9,PERCENT
%,PERCENT
),O
of,O
patients,O
within,O
28,NUMBER
days,DURATION
of,O
presentation,O
.,O
Of,O
these,O
.,O
537,NUMBER
(,O
62,PERCENT
%,PERCENT
),O
occurred,O
within,O
1,DURATION
day,DURATION
.,O
and,O
782,NUMBER
(,O
91,PERCENT
%,PERCENT
),O
occurred,O
within,O
7,DURATION
days,DURATION
.,O
These,O
numbers,O
support,O
our,O
choice,O
of,O
7,DURATION
days,DURATION
as,O
a,O
clinically,O
meaningful,O
event,O
prediction,O
horizon,O
.,O
Curves,O
for,O
the,O
cumulative,O
incidence,O
of,O
adverse,O
events,O
over,O
time,O
for,O
different,O
Predictors,O
of,O
Adverse,O
Events,O
predictors,O
increase,O
the,O
predicted,O
probability,O
of,O
adverse,O
events,O
when,O
present,DATE
.,O
SpO2,O
.,O
diastolic,O
and,O
systolic,O
blood,O
pressure,O
and,O
low,O
BMI,O
inversely,O
correlated,O
with,O
the,O
probability,O
of,O
adverse,O
events,O
.,O
Pre,O
‐,O
dictors,O
from,O
CXR,ORGANIZATION
reports,O
included,O
in,O
the,O
model,TITLE
were,O
multifocal,O
patterns,O
(,O
diffuse,O
opacities,O
.,O
ground,O
glass,O
),O
and,O
patterns,O
typical,O
for,O
COVID,O
.,O
Effect,O
of,O
Chest,O
X,O
‐,O
Ray,O
Findings,O
and,O
COVID,O
Status,O
on,O
the,O
Probability,O
of,O
Adverse,O
Events,O
CXRs,O
and,O
testing,O
for,O
COVID,O
‐,O
19,NUMBER
were,O
not,O
universal,O
.,O
and,O
testing,O
rates,O
evolved,O
over,O
time,O
.,O
One,NUMBER
po,O
‐,O
tential,O
use,O
of,O
CoVA,O
is,O
to,O
help,O
determine,O
whether,O
to,O
perform,O
these,O
tests,O
.,O
We,O
therefore,O
investigated,O
the,O
impact,O
of,O
S4,O
.,O
positive,O
CXR,O
findings,O
are,O
most,O
informative,O
when,O
the,O
pre,O
‐,O
CXR,O
probability,O
is,O
30,PERCENT
%,PERCENT
(,O
critical,O
illness,CAUSE_OF_DEATH
or,O
death,O
),O
.,O
in,O
which,O
case,O
they,O
increase,O
the,O
pre,O
‐,O
dicted,O
probability,O
of,O
an,O
adverse,O
event,O
by,O
4,PERCENT
%,PERCENT
.,O
Negative,O
CXR,O
find,O
‐,O
ings,O
are,O
maximally,O
informative,O
when,O
the,O
pretest,O
probability,O
is,O
near,O
34,PERCENT
%,PERCENT
(,O
critical,O
illness,CAUSE_OF_DEATH
or,O
death,O
),O
.,O
in,O
which,O
case,O
they,O
decrease,O
the,O
probability,O
by,O
4,PERCENT
%,PERCENT
.,O
We,O
also,O
examined,O
the,O
effect,O
of,O
COVID,O
‐,O
19,NUMBER
testing,O
results,O
on,O
the,O
predicted,O
probability,O
of,O
adverse,O
events,O
(,O
critical,O
illness,CAUSE_OF_DEATH
or,O
death,O
),O
.,O
The,O
largest,O
effect,O
of,O
a,O
positive,O
test,O
result,O
occurs,O
when,O
pretest,O
probability,O
is,O
28,PERCENT
%,PERCENT
.,O
in,O
which,O
case,O
the,O
post,O
‐,O
test,O
probability,O
increases,O
by,O
8,PERCENT
%,PERCENT
.,O
A,O
negative,O
result,O
has,O
the,O
largest,O
impact,O
when,O
pretest,O
probability,O
is,O
36,PERCENT
%,PERCENT
.,O
in,O
which,O
case,O
the,O
posttest,O
probability,O
decreases,O
by,O
8,PERCENT
%,PERCENT
.,O
Identifying,O
outpa,O
‐,O
tients,O
presenting,O
for,O
COVID,O
‐,O
19,NUMBER
screening,O
at,O
high,O
risk,O
or,O
low,O
risk,O
for,O
adverse,O
events,O
is,O
important,O
for,O
medical,O
decisions,O
regarding,O
testing,O
.,O
hospitalization,O
.,O
and,O
follow,O
‐,O
up,O
.,O
We,O
developed,O
and,O
score,O
that,O
can,O
be,O
implemented,O
in,O
the,O
EMR,O
.,O
The,O
model,TITLE
exhibits,O
excellent,O
calibration,O
.,O
discrimination,O
.,O
and,O
negative,O
predictive,O
value,O
both,O
in,O
concurrent,O
validation,O
(,O
n,O
=,O
9381,NUMBER
.,O
March,DATE
7,DATE
‐,O
May,DATE
2,DATE
),O
and,O
in,O
large,O
‐,O
scale,O
prospective,O
validation,O
(,O
n,O
=,O
2205,DATE
.,DATE
May,DATE
3,DATE
‐,O
14,NUMBER
),O
.,O
While,O
several,O
COVID,O
‐,O
19,NUMBER
risk,O
prediction,O
models,O
have,O
been,O
proposed,O
for,O
the,O
inpa,O
‐,O
tient,O
setting,O
.,O
CoVA,O
fills,O
an,O
unmet,O
need,O
for,O
a,O
prospectively,O
vali,O
‐,O
dated,O
risk,O
designed,O
for,O
outpatient,O
screening,O
.,O
Several,O
predictors,O
selected,O
into,O
the,O
model,TITLE
have,O
been,O
identified,O
in,O
prior,O
studies,O
.,O
including,O
advanced,O
age,O
[,O
4.5.9.19,NUMBER
],O
;,O
pre,O
‐,O
existing,O
pulmonary,O
[,O
4.5,NUMBER
],O
.,O
kidney,O
[,O
4,NUMBER
],O
.,O
and,O
cardiovascular,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
[,O
4.9.20,NUMBER
],O
;,O
obesity,O
[,O
21,NUMBER
],O
;,O
and,O
increased,O
respiratory,O
or,O
heart,O
rate,O
or,O
hypoxia,O
[,O
4,NUMBER
],O
.,O
We,O
found,O
that,O
other,O
pre,O
‐,O
existing,O
medical,O
conditions,O
also,O
increased,O
risk,O
for,O
ad,O
‐,O
verse,O
outcomes,O
.,O
including,O
hematologic,O
malignancy,O
.,O
cancer,CAUSE_OF_DEATH
and,O
pan,O
‐,O
creatitis,O
.,O
Hypertension,CAUSE_OF_DEATH
and,O
diabetes,CAUSE_OF_DEATH
mellitus,CAUSE_OF_DEATH
did,O
not,O
emerge,O
as,O
predictors,O
in,O
the,O
CoVA,MISC
model,TITLE
.,O
despite,O
being,O
identified,O
in,O
prior,O
studies,O
[,O
4,NUMBER
.,O
5,NUMBER
.,O
9,NUMBER
],O
.,O
These,O
comorbidities,O
are,O
correlated,O
with,O
out,O
‐,O
comes,O
in,O
univariate,O
analysis,O
higher,O
CCI,ORGANIZATION
.,O
high,O
BMI,O
.,O
and,O
other,O
co,O
‐,O
morbidities,O
already,O
selected,O
as,O
predictors,O
.,O
helping,O
to,O
explain,O
their,O
not,O
the,O
outcome,O
.,O
but,O
this,DATE
may,DATE
have,O
been,O
due,O
to,O
low,O
numbers,O
(,O
85/9381,NUMBER
<,O
1,PERCENT
%,PERCENT
.,O
less,O
than,O
1,PERCENT
%,PERCENT
of,O
developmental,O
Several,O
studies,O
have,O
documented,O
neurological,O
manifestation,O
of,O
COVID,O
‐,O
19,NUMBER
[,O
2224,DATE
],O
.,O
Never,O
‐,O
theless,O
.,O
we,O
were,O
surprised,O
to,O
find,O
a,O
variety,O
of,O
neurological,O
dis,O
‐,O
eases,O
surfaced,O
as,O
robust,O
predictors,O
of,O
adverse,O
outcomes,O
in,O
COVID,O
‐,O
19,NUMBER
infection,CAUSE_OF_DEATH
.,O
including,O
ischemic,O
stroke,CAUSE_OF_DEATH
.,O
intracranial,O
hem,O
‐,O
orrhage,O
.,O
subarachnoid,O
hemorrhage,CAUSE_OF_DEATH
.,O
epilepsy,CAUSE_OF_DEATH
.,O
amyotrophic,O
lateral,O
sclerosis,O
.,O
myasthenia,O
gravis,O
.,O
and,O
spinal,O
muscular,O
atrophy,O
.,O
It,O
is,O
unclear,O
if,O
these,O
neurological,O
diseases,CAUSE_OF_DEATH
are,O
merely,O
markers,O
of,O
health,O
or,O
if,O
the,O
worsened,O
outcomes,O
are,O
due,O
to,O
the,O
interaction,O
of,O
COVID,O
‐,O
19,NUMBER
with,O
neurological,O
disorders,O
that,O
amplifies,O
the,O
patholo,O
‐,O
gy,O
.,O
our,O
study,O
.,O
most,O
have,O
attempted,O
to,O
predict,O
critical,O
illness,CAUSE_OF_DEATH
or,O
death,O
.,O
However,O
.,O
most,O
are,O
based,O
on,O
small,O
cohorts,O
(,O
median,O
:,O
n,O
=,O
189,NUMBER
.,O
range,O
n,O
=,O
26,NUMBER
to,O
577,NUMBER
),O
;,O
focus,O
on,O
inpatients,O
;,O
and,O
utilize,O
labo,O
‐,O
ratory,O
values,O
.,O
which,O
were,O
rarely,O
available,O
for,O
our,O
outpatient,O
co,O
‐,O
hort,O
.,O
Only,O
3,NUMBER
included,O
prospective,O
or,O
external,O
validation,O
.,O
By,O
con,O
‐,O
trast,O
.,O
CoVA,O
is,O
designed,O
for,O
the,O
outpatient,O
setting,O
.,O
In,O
this,O
set,O
‐,O
ting,O
.,O
the,O
availability,O
of,O
COVID,O
‐,O
19,NUMBER
test,O
results,O
are,O
variably,O
available,O
(,O
for,O
60,PERCENT
%,PERCENT
in,O
the,O
development,O
and,O
80,PERCENT
%,PERCENT
in,O
the,O
prospective,O
cohort,O
),O
and,O
other,O
laboratory,O
results,O
were,O
rarely,O
available,O
.,O
To,O
ensure,O
generalizability,O
.,O
we,O
used,O
a,O
large,O
development,O
cohort,O
of,O
9381,NUMBER
patients,O
.,O
and,O
trained,O
the,O
model,TITLE
using,O
a,O
rigorous,O
approach,O
.,O
We,O
ensured,O
clinical,O
interpretability,O
by,O
utilizing,O
a,O
linear,O
model,TITLE
with,O
positivity,O
constraints,O
on,O
predictors,O
expected,O
to,O
increase,O
risk,O
.,O
Finally,O
.,O
we,O
validated,O
our,O
model,TITLE
on,O
a,O
large,O
(,O
n,O
=,O
2205,DATE
),O
prospectively,O
collected,O
patient,O
cohort,O
.,O
providing,O
an,O
unbiased,O
as,O
‐,O
sessment,O
of,O
model,TITLE
generalizability,O
.,O
Strengths,O
of,O
this,O
study,O
in,O
‐,O
clude,O
its,O
large,O
sample,O
size,O
.,O
careful,O
EMR,O
phenotyping,O
.,O
rigorous,O
statistical,O
approach,O
.,O
and,O
the,O
feature,O
that,O
all,O
variables,O
required,O
by,O
the,O
model,TITLE
are,O
available,O
and,O
automatically,O
from,O
a,O
single,O
cen,O
‐,O
ter,TITLE
.,O
with,O
patient,O
demographics,O
specific,O
to,O
MGH,ORGANIZATION
.,O
Boston,CITY
.,O
Neverthe,O
‐,O
less,O
.,O
important,O
biological,O
parameters,O
in,O
the,O
predictive,O
model,TITLE
are,O
universal,O
and,O
increase,O
the,O
likelihood,O
that,O
the,O
model,TITLE
will,O
gener,O
‐,O
alize,O
.,O
Second,ORDINAL
.,O
although,O
RIC,O
clinics,O
were,O
established,O
for,O
patients,O
with,O
suspicion,O
for,O
COVID,O
‐,O
19,NUMBER
.,O
patients,O
seen,O
in,O
the,O
ED,O
were,O
seen,O
for,O
a,O
variety,O
of,O
reasons,O
.,O
Nevertheless,O
COVID,O
‐,O
19,NUMBER
was,O
and,O
for,O
now,DATE
remains,O
a,O
universal,O
concern,O
for,O
patients,O
seen,O
in,O
the,O
ED,O
.,O
and,O
we,O
excluded,O
patients,O
prior,O
to,O
the,O
onset,O
of,O
COVID,O
‐,O
19,NUMBER
in,O
Boston,CITY
(,O
March,DATE
7,NUMBER
.,O
2020,DATE
),O
.,O
therefore,O
our,O
model,TITLE
is,O
relevant,O
for,O
screening,O
during,O
times,O
of,O
high,O
alert,O
for,O
COVID,O
‐,O
19,NUMBER
.,O
Finally,O
.,O
we,O
did,O
not,O
include,O
lab,O
test,O
values,O
.,O
since,O
they,O
were,O
typically,O
not,O
available,O
.,O
Among,O
the,O
few,O
studies,O
of,O
inpatients,O
.,O
inclusion,O
of,O
lab,O
tests,O
appears,O
to,O
im,O
‐,O
prove,O
model,TITLE
performance,O
.,O
In,O
conclusion,O
.,O
the,O
COVID,O
‐,O
19,NUMBER
Acuity,O
Score,O
(,O
CoVA,O
),O
represents,O
a,O
well,O
‐,O
calibrated,O
.,O
discriminative,O
.,O
pre,O
‐,O
senting,O
with,O
possible,O
COVID,O
‐,O
19,NUMBER
infection,CAUSE_OF_DEATH
.,O
Respiratory,CAUSE_OF_DEATH
Infection,CAUSE_OF_DEATH
Clinics,O
in,O
the,O
MassGeneral,O
Brigham,O
hospital,O
system,O
.,O
and,O
the,O
MGH,ORGANIZATION
Emergency,O
Departments,O
for,O
their,O
constructive,O
feedback,O
on,O
this,O
work,O
.,O
Center,O
for,O
AIDS,CAUSE_OF_DEATH
Research,MISC
(,O
HU,O
CFAR,O
NIH,O
/,O
NIAID,ORGANIZATION
fund,O
5P30AI060354,O
‐,O
16,NUMBER
),O
.,O
MBW,O
was,O
supported,O
by,O
the,O
Glenn,ORGANIZATION
Foundation,ORGANIZATION
for,O
Medical,ORGANIZATION
Research,ORGANIZATION
and,ORGANIZATION
American,ORGANIZATION
Federation,ORGANIZATION
for,ORGANIZATION
Aging,ORGANIZATION
Research,ORGANIZATION
through,O
a,O
Breakthroughs,O
in,O
Gerontology,O
Grant,O
;,O
the,O
American,NATIONALITY
Acade,MISC
‐,O
my,O
of,O
Sleep,O
Medicine,O
through,O
an,O
AASM,ORGANIZATION
Foundation,ORGANIZATION
Strategic,ORGANIZATION
Re,ORGANIZATION
‐,O
search,O
Award,O
;,O
the,O
Department,ORGANIZATION
of,ORGANIZATION
Defense,ORGANIZATION
through,O
a,O
subcontract,O
from,O
Moberg,ORGANIZATION
ICU,ORGANIZATION
Solutions,ORGANIZATION
.,ORGANIZATION
Inc,ORGANIZATION
.,O
and,O
by,O
grants,O
from,O
the,O
NIH,ORGANIZATION
(,O
1R01NS102190,O
.,O
1R01NS102574,O
.,O
1R01NS107291,O
.,O
1RF1AG064312,O
),O
.,O
Dr.,O
Westover,PERSON
is,O
co,O
‐,O
founder,TITLE
of,O
Beacon,O
Biosignals,O
.,O
S.M.,PERSON
was,O
supported,O
by,O
the,O
National,ORGANIZATION
Division,ORGANIZATION
of,ORGANIZATION
Clinical,ORGANIZATION
Research,ORGANIZATION
.,O
BF,O
was,O
supported,O
by,O
the,O
BRAIN,MISC
Initiative,MISC
Cell,MISC
Census,MISC
Network,MISC
grant,O
U01MH117023,O
.,O
the,O
NIBIB,O
(,O
P41EB015896,O
.,O
1R01EB023281,O
.,O
R01EB006758,O
.,O
R21EB018907,O
.,O
R01EB019956,O
),O
.,O
NIA,O
(,O
1R56AG064027,O
.,O
1R01AG064027,O
.,O
5R01AG008122,O
.,O
R01AG016495,O
),O
.,O
NIHM,ORGANIZATION
and,O
NIMDKD,O
(,O
1,NUMBER
‐,O
R21,O
‐,O
DK,O
‐,O
108277,NUMBER
‐,O
01,NUMBER
),O
.,O
NINDS,PERSON
(,O
R01NS0525851,O
.,O
R21NS072652,O
.,O
R01NS070963,O
.,O
R01NS083534,O
.,O
5U01NS086625,O
.5,O
U24NS10059103,O
.,O
R01NS105820,O
),O
.,O
and,O
Shared,O
Instrumen,O
‐,O
tation,O
Grants,O
1S10RR023401,O
.,O
1S10RR019307,O
.,O
and,O
1S10RR023043,O
.,O
BF,O
received,O
additional,O
support,O
from,O
the,O
NIH,O
Blueprint,O
for,O
Neuro,O
‐,O
science,O
Research,O
(,O
5U01,O
‐,O
MH093765,O
),O
.,O
part,O
of,O
the,O
Human,O
Connectome,O
Project,O
.,O
In,O
addition,O
.,O
BF,ORGANIZATION
has,O
a,O
financial,O
interest,O
in,O
CorticoMet,O
‐,O
rics,O
.,O
a,O
company,O
whose,O
medical,O
pursuits,O
focus,O
on,O
brain,O
General,TITLE
Hospital,O
and,O
Partners,ORGANIZATION
HealthCare,ORGANIZATION
in,O
accordance,O
with,O
their,O
con,O
‐,O
flict,O
of,O
interest,O
policies,O
.,O
S,O
R,O
.,O
Js,O
H,O
.,O
M,O
N,O
.,O
et,O
al,O
.,O
Presenting,O
Characteristics,MISC
.,O
Comorbidities,O
.,O
and,O
Outcomes,O
Among,O
5700,NUMBER
Patients,O
Hospitalized,O
With,O
COVID,O
‐,O
19,NUMBER
in,O
the,O
New,CITY
York,CITY
City,CITY
Area,LOCATION
.,O
JAMA,ORGANIZATION
.,O
2020,DATE
.,O
Available,O
at,O
:,O
Covid,O
‐,O
19,NUMBER
Navigating,O
the,O
Uncharted,O
|,O
NEJM,O
.,O
N,O
Engl,PERSON
J,PERSON
Med,O
Available,O
at,O
:,O
Zhou,O
F,O
.,O
Yu,PERSON
T,PERSON
.,O
Du,PERSON
R,PERSON
.,O
et,O
al,O
.,O
Clinical,O
course,O
and,O
risk,O
factors,O
for,O
mortality,O
of,O
adult,O
inpatients,O
with,O
COVID,O
‐,O
19,NUMBER
in,O
Wuhan,CITY
.,O
China,COUNTRY
:,O
a,O
retrospective,O
cohort,O
study,O
.,O
The,O
Lancet,O
2020,DATE
;,O
395:10541062,NUMBER
.,O
Wu,O
Z,O
.,O
McGoogan,PERSON
JM,PERSON
.,O
Characteristics,O
of,O
and,O
Impor,O
‐,O
tant,O
Lessons,O
From,O
the,O
Coronavirus,O
Disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
Out,O
‐,O
break,O
in,O
China,COUNTRY
:,O
Summary,O
of,O
a,O
Report,O
of,O
72,NUMBER
314,NUMBER
Cases,O
From,O
the,O
Chi,O
‐,O
nese,O
Center,ORGANIZATION
for,ORGANIZATION
Disease,ORGANIZATION
Control,ORGANIZATION
and,ORGANIZATION
Prevention,ORGANIZATION
.,O
JAMA,O
2020,DATE
;,O
CDC,ORGANIZATION
COVID,O
‐,O
19,NUMBER
Response,O
Team,O
.,O
Severe,O
Outcomes,O
Among,O
Patients,O
with,O
Coro,O
‐,O
navirus,O
Disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
‐,O
United,COUNTRY
States,COUNTRY
.,O
February,DATE
12,NUMBER
‐,O
March,DATE
16,DATE
.,DATE
2020,DATE
.,O
MMWR,MISC
Morb,MISC
Mortal,MISC
Wkly,MISC
Rep,TITLE
He,O
X,O
.,O
Lau,LOCATION
EHY,LOCATION
.,O
Wu,PERSON
P,PERSON
.,O
et,O
al,O
.,O
Temporal,O
dynamics,O
in,O
viral,O
shedding,O
and,O
transmissibility,O
of,O
COVID19,O
.,O
Nat,O
Med,O
2020,DATE
;,O
26:672675,NUMBER
.,O
Lauer,ORGANIZATION
SA,ORGANIZATION
.,O
Grantz,PERSON
KH,PERSON
.,O
Bi,O
Q,O
.,O
et,O
al,O
.,O
The,O
Incubation,O
Period,O
of,O
Coronavirus,O
Disease,CAUSE_OF_DEATH
2019,DATE
(,O
COVID,O
‐,O
19,NUMBER
),O
From,O
Publicly,O
Reported,O
Confirmed,O
Cases,O
:,O
Estimation,O
and,O
Application,O
.,O
Ann,O
Intern,TITLE
Med,O
2020,DATE
;,O
D,O
W,O
.,O
B,O
H,O
.,O
C,O
H,O
.,O
et,O
al,O
.,O
Clinical,O
Characteristics,O
of,O
138,NUMBER
Hospitalized,O
Patients,O
With,O
2019,DATE
Novel,O
Coronavirus,O
‐,O
Infected,O
Pneumonia,CAUSE_OF_DEATH
in,O
Wuhan,CITY
.,O
China,COUNTRY
.,O
JAMA,ORGANIZATION
.,O
2020,DATE
.,O
Available,O
at,O
:,O
Accessed,O
5,DATE
June,DATE
2020,DATE
.,O
Holshue,ORGANIZATION
ML,ORGANIZATION
.,O
DeBolt,PERSON
C,O
.,O
Lindquist,PERSON
S,O
.,O
et,O
al,O
.,O
First,ORDINAL
Case,O
of,O
2019,DATE
Novel,O
Coronavirus,O
in,O
the,O
United,COUNTRY
States,COUNTRY
.,O
N,O
Engl,O
J,O
Med,O
2020,DATE
;,O
382:929936,NUMBER
.,O
The,O
Covid,O
‐,O
19,NUMBER
Tracker,O
.,O
STAT,O
.,O
2020,DATE
;,O
Available,O
at,O
:,O
Staff,O
JSG,O
.,O
April,DATE
17,DATE
U,O
.,O
2020,DATE
.,O
Comments127,O
6:26,TIME
p,O
m,O
Email,O
to,O
a,O
Friend,O
Share,O
on,O
Facebook,O
Share,O
on,O
to,O
coronavirus,O
‐,O
The,O
Boston,ORGANIZATION
Globe,ORGANIZATION
.,O
Available,O
at,O
:,O
Results,O
released,O
for,O
antibody,O
and,O
COVID,O
‐,O
19,NUMBER
testing,O
of,O
Boston,CITY
residents,O
.,O
2020,DATE
.,O
Available,O
at,O
:,O
Accessed,O
9,DATE
June,DATE
2020,DATE
.,O
Gasparini,PERSON
A.,O
comorbidity,O
:,O
An,O
R,O
package,O
for,O
computing,O
comorbidity,O
scores,O
.,O
J,O
Open,O
Source,O
Softw,PERSON
Batista,ORGANIZATION
GE,ORGANIZATION
.,O
Monard,O
MC,O
.,O
A,O
Study,O
of,O
K,O
‐,O
Nearest,O
Neighbour,O
as,O
an,O
Impu,O
‐,O
tation,O
Method,O
.,O
His,O
2002,DATE
;,O
Pedregosa,O
F,O
.,O
Varoquaux,PERSON
G,PERSON
.,O
Gramfort,O
A,O
.,O
et,O
al,O
.,O
Scikit,O
‐,O
learn,O
:,O
Machine,O
learning,O
in,O
Python,PERSON
.,O
J,PERSON
Mach,PERSON
Learn,PERSON
Res,PERSON
2011,DATE
;,O
12:28252830,NUMBER
.,O
Liu,PERSON
T,O
‐,O
Y.,O
Learning,O
to,O
rank,O
for,O
information,O
re,O
‐,O
trieval,O
.,O
Found,O
Trends,O
Inf,O
Retr,O
2009,DATE
;,O
3:225331,NUMBER
.,O
Vergouwe,O
Y,O
.,O
Steyerberg,ORGANIZATION
EW,ORGANIZATION
.,O
Eijkemans,ORGANIZATION
MJC,ORGANIZATION
.,O
Habbema,ORGANIZATION
JDF,ORGANIZATION
.,O
Validity,O
of,O
prognostic,O
models,O
:,O
when,O
is,O
a,O
model,TITLE
clinically,O
useful,O
?,O
Semin,O
Urol,O
Oncol,O
2002,DATE
;,O
20:96107,NUMBER
.,O
Guan,O
W,O
‐,O
J,O
.,O
Ni,MISC
Z,O
‐,O
Y,O
.,O
Hu,O
Y,O
.,O
et,O
al,O
.,O
Clinical,O
Characteris,O
‐,O
tics,O
of,O
Coronavirus,O
Disease,CAUSE_OF_DEATH
2019,DATE
in,O
China,COUNTRY
.,O
N,O
Engl,O
J,O
Med,O
2020,DATE
;,O
382:17081720,NUMBER
.,O
Ruan,PERSON
Q,O
.,O
Yang,PERSON
K,PERSON
.,O
Wang,PERSON
W,PERSON
.,O
Jiang,PERSON
L,O
.,O
Song,PERSON
J.,PERSON
Clinical,PERSON
predictors,O
of,O
mortality,O
due,O
to,O
COVID,O
‐,O
19,NUMBER
based,O
on,O
an,O
analysis,O
of,O
data,O
of,O
150,NUMBER
patients,O
from,O
Wuhan,CITY
.,O
China,COUNTRY
.,O
Intensive,O
Care,O
Med,O
2020,DATE
;,O
46:846,NUMBER
Cai,O
Q,O
.,O
Chen,PERSON
F,PERSON
.,O
Wang,PERSON
T,PERSON
.,O
et,O
al,O
.,O
Obesity,O
and,O
COVID,O
‐,O
19,NUMBER
Severi,O
‐,O
ty,O
in,O
a,O
Designated,O
Hospital,O
in,O
Shenzhen,CITY
.,O
China,COUNTRY
.,O
Diabetes,CAUSE_OF_DEATH
Care,O
2020,DATE
;,O
Filatov,PERSON
A,O
.,O
Sharma,PERSON
P,O
.,O
Hindi,O
F,O
.,O
Espinosa,PERSON
PS,O
.,O
Neurological,O
Complications,CAUSE_OF_DEATH
of,O
Coronavirus,O
Disease,CAUSE_OF_DEATH
(,O
COVID,O
‐,O
19,NUMBER
),O
:,O
Encephalopathy,O
.,O
Cureus,O
12,NUMBER
.,O
Available,O
at,O
:,O
Mao,PERSON
L,PERSON
.,O
Jin,PERSON
H,PERSON
.,O
Wang,PERSON
M,O
.,O
et,O
al,O
.,O
Neurologic,O
Manifestations,O
of,O
Hospitalized,O
Patients,O
With,O
Coronavirus,O
Disease,CAUSE_OF_DEATH
2019,DATE
in,O
Wuhan,CITY
.,O
China,COUNTRY
.,O
JAMA,ORGANIZATION
Neurol,O
2020,DATE
;,O
Wu,O
Y,O
.,O
Xu,PERSON
X,PERSON
.,O
Chen,PERSON
Z,PERSON
.,O
et,O
al,O
.,O
Nervous,O
system,O
involvement,O
after,O
infection,CAUSE_OF_DEATH
with,O
COVID,O
‐,O
19,NUMBER
and,O
other,O
coronaviruses,O
.,O
Brain,O
Behav,O
Immun,O
2020,DATE
;,O
Available,O
at,O
:,O
emer,O
‐,O
gency,O
department,O
.,O
ICU,O
=,O
intensive,O
care,O
unit,O
.,O
BMI,O
=,O
body,O
mass,O
in,O
‐,O
dex,O
.,O
HR,DURATION
=,O
heart,O
rate,O
.,O
SpO2,O
=,O
oxygen,O
saturation,O
;,O
CCI,ORGANIZATION
=,O
Charlson,PERSON
Comorbidity,O
Index,O
.,O
Development,O
cohort,O
Prospective,O
cohort,O
RIC,O
:,O
n,O
(,O
%,O
),O
ED,O
:,O
n,O
(,O
%,O
),O
Yes,O
:,O
n,O
(,O
%,O
),O
No,O
:,O
n,O
(,O
%,O
),O
Untested,O
or,O
Unknown,O
:,O
n,O
(,O
%,O
),O
Hospitalization,O
:,O
n,O
(,O
%,O
),O
ICU,O
or,O
Intubation,O
:,O
n,O
(,O
%,O
),O
Death,O
:,O
n,O
(,O
%,O
),O
Age,O
.,O
year,DURATION
:,O
Mean,O
(,O
SD,STATE_OR_PROVINCE
),O
Female,O
:,O
n,O
(,O
%,O
),O
BMI,O
.,O
kg,O
/,O
m2,O
:,O
Mean,O
(,O
SD,STATE_OR_PROVINCE
),O
Asian,NATIONALITY
:,O
n,O
(,O
%,O
),O
Black,O
:,O
n,O
(,O
%,O
),O
Pacific,O
Islander,O
:,O
n,O
(,O
%,O
),O
Native,MISC
American,NATIONALITY
:,O
n,O
(,O
%,O
),O
White,O
:,O
n,O
(,O
%,O
),O
Other,O
or,O
Unknown,O
:,O
n,O
(,PERCENT
%,PERCENT
),O
Yes,O
/,O
Quit,O
:,O
n,O
(,O
%,O
),O
Never,O
/,O
Passive,O
:,O
n,O
(,O
%,O
),O
Not,O
Asked,O
/,O
Unknown,O
:,O
n,O
(,O
%,O
),O
Weighted,O
Charlson,PERSON
Score,O
:,O
Mean,O
(,O
SD,STATE_OR_PROVINCE
),O
SpO2,O
.,O
%,O
:,O
Mean,O
(,O
SD,STATE_OR_PROVINCE
),O
Outcome,O
in,O
7,DURATION
days,DURATION
Hispanic,O
Ethnicity,O
:,O
n,O
(,O
%,O
),O
Chest,O
X,O
‐,O
ray,O
(,O
percentage,O
is,O
among,O
available,O
pa,O
‐,O
tients,O
except,O
the,O
first,ORDINAL
one,NUMBER
),O
Chest,O
X,O
‐,O
ray,O
available,O
:,O
n,O
(,O
%,O
),O
Multi,O
‐,O
focal,O
:,O
n,O
(,O
%,O
),O
Typical,O
pattern,O
for,O
COVID,O
‐,O
19,NUMBER
:,O
n,O
(,O
%,O
),O
Patchy,O
consoli,O
‐,O
dation,O
:,O
n,O
(,O
%,O
),O
Peripheral,O
/,O
interstitial,O
opacity,O
:,O
n,O
(,O
%,O
),O
Hazy,O
or,O
airspace,O
opacity,O
:,O
n,O
(,O
%,O
),O
characteristic,O
curve,O
.,O
PPV,O
=,O
positive,O
pressure,O
ventilation,O
.,O
NPV,O
=,O
negative,O
predictive,O
value,O
.,O
Adverse,O
event,O
Hospitalization,O
.,O
ICU,O
.,O
Intubation,O
.,O
or,O
death,O
ICU,O
.,O
Intubation,O
.,O
or,O
Concurrent,O
validation,O
(,O
based,O
on,O
the,O
development,O
cohort,O
but,O
cross,O
‐,O
validated,O
),O
Number,O
of,O
patients,O
(,O
n,O
.,O
%,O
),O
Calibration,O
slope,O
(,O
CS,O
),O
Spec,O
.,O
at,O
90,PERCENT
%,PERCENT
Sens.,O
PPV,O
at,O
90,PERCENT
%,PERCENT
Sens.,O
NPV,O
at,O
90,PERCENT
%,PERCENT
Sens.,O
Prospec,O
‐,O
tive,O
validation,O
Number,O
of,O
patients,O
(,O
n,O
.,O
%,O
),O
Calibration,O
slope,O
(,O
CS,O
),O
Spec,O
.,O
at,O
90,PERCENT
%,PERCENT
Sens.,O
PPV,O
at,O
90,PERCENT
%,PERCENT
Sens.,O
NPV,O
at,O
90,PERCENT
%,PERCENT
Sens.,O
+,O
95,PERCENT
%,PERCENT
confidence,O
interval,O
PPV,O
=,O
positive,O
predictive,O
value,O
.,O
NPV,O
=,O
nega,O
‐,O
tive,O
predictive,O
value,O
.,O
Spec,O
=,O
specificity,O
.,O
Sens,O
=,O
sensitivity,O
.,O
ICU,O
=,O
intensive,O
care,O
unit,O
.,O
E,O
/,O
O,O
=,O
ratio,O
of,O
Expected,O
to,O
number,O
of,O
Observed,O
adverse,O
events,O
.,O
n.c.,O
=,O
not,O
calculated,O
due,O
to,O
small,O
sam,O
‐,O
ple,O
size,O
.,O
Renal,O
cancer,CAUSE_OF_DEATH
*,O
Diastolic,MISC
blood,O
pressure,O
Cystic,MISC
fibro,O
‐,O
sis,O
*,O
Ever,O
COVID,O
+,O
up,O
to,O
event,O
Cardiac,CAUSE_OF_DEATH
Arrest,CAUSE_OF_DEATH
*,O
Seizure,O
disorder,O
Amyolateral,O
sclerosis,O
*,O
Metabolic,O
acidosis,O
*,O
Myasthenia,O
gravis,O
*,O
Respiratory,O
Rate,O
Acute,O
ischemic,O
stroke,CAUSE_OF_DEATH
*,O
CXR,O
:,O
Multifocal,O
Heart,O
rate,O
Body,O
temperature,O
Systolic,MISC
blood,O
pressure,O
Spinal,O
muscular,O
at,O
‐,O
rophy,O
*,O
Weighted,O
Charlson,PERSON
Score,O
Intracranial,O
hemorrhage,CAUSE_OF_DEATH
*,O
Subarach,O
‐,O
noid,O
hemorrhage,CAUSE_OF_DEATH
*,O
Male,O
sex,O
High,O
BMI,O
(,O
>,O
35kg,NUMBER
/,O
m,O
),O
CXR,O
:,O
Typical,O
for,O
COVID,O
Low,O
BMI,O
(,O
<,O
18.5,NUMBER
kg,O
/,O
m,O
),O
Hematologic,O
malignancy,O
*,O
Legend,O
:,O
Abbre,O
‐,O
viations,O
:,O
CXR,O
=,O
chest,O
X,O
‐,O
ray,O
;,O
ARDS,O
=,O
Acute,O
Respiratory,O
Distress,O
Syndrome,O
;,O
BMI,MISC
=,MISC
Body,MISC
Mass,STATE_OR_PROVINCE
Index,MISC
.,O
Diagnoses,O
are,O
based,O
on,O
past,DATE
med,O
‐,O
ical,O
history,O
.,O
and,O
are,O
coded,O
as,O
present,DATE
(,O
e.g.,O
Pneumothorax,O
=,O
1,NUMBER
),O
if,O
recorded,O
in,O
the,O
electronic,O
medical,O
record,O
at,O
any,O
time,O
before,O
the,O
date,O
of,O
presentation,O
for,O
COVID,O
‐,O
19,NUMBER
screening,O
.,O
Disorders,O
marked,O
by,O
*,O
refer,O
to,O
pre,O
‐,O
existing,O
conditions,O
documented,O
in,O
the,O
electronic,O
medical,O
record,O
.,O
RIC,O
/,O
ED,O
.,O
binned,O
by,O
acuity,O
score,O
.,O
Colors,O
represent,O
hospitalization,O
.,O
ICU,O
/,O
MV,O
.,O
or,O
death,O
.,O
(,O
B,O
),O
Cumulative,O
incidence,O
of,O
critical,O
illness,CAUSE_OF_DEATH
or,O
death,O
up,DURATION
to,DURATION
17,DURATION
days,DURATION
following,O
initial,O
evalua,O
‐,O
tion,O
.,O
based,O
on,O
initial,O
acuity,O
score,O
.,O
Curves,O
are,O
computed,O
based,O
on,O
cross,O
validation,O
in,O
the,O
development,O
cohort,O
(,O
C,O
.,O
D,O
.,O
E,O
.,O
F,O
),O
Calibration,O
curves,O
:,O
predicted,O
probability,O
of,O
adverse,O
events,O
vs.,O
observed,O
rate,O
of,O
adverse,O
events,O
.,O
C,O
(,O
development,O
cohort,O
),O
and,O
D,O
(,O
prospective,O
val,O
‐,O
idation,O
cohort,O
),O
show,O
calibration,O
for,O
predicting,O
hospitalization,O
;,O
E,O
(,O
development,O
cohort,O
),O
and,O
F,O
(,O
prospective,O
validation,O
cohort,O
),O
show,O
calibration,O
for,O
predictions,O
of,O
critical,O
